Dermatology

Eric Simpson, MD, MCR, FAAD, lead author of a recently-published article highlighting roflumilast cream 0.15%, joined us for a Q+A interview.

With this acceptance, the federal agency has assigned a PDUFA date of May 22, 2025 for roflumilast foam (Zoryve) 0.3%.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The indication is supported by trial data showing three-fourths of successfully treated patients maintained clear skin through 1 year of a lebrikizumab regimen.

Can you diagnose this adolescent with an 11-day history of diffuse targetoid and bullous lesions on his extremities and trunk?

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the August 2024 issue of Contemporary Pediatrics.

Efficacy of roflumilast cream 0.05% improved over time among children aged 2 to 5 years with mild to moderate atopic dermatitis.

Donna Hallas PhD, PPCNP-BC, CPNP, PMHS, FAANP FAAN, highlights the August issue of our journal with commentary and recommendations.

Standard treatment for vitiligo includes topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids, and phototherapy, among others.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the August 2024 issue of Contemporary Pediatrics.

Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.

If approved, roflumilast foam 0.3% for scalp and body psoriasis treatment would add to the multiple already-approved roflumilast indications.

Details of newly FDA-approved roflumilast cream 0.15% for AD in pediatric patients, plus insight and commentary from Lawrence Eichenfield, MD.

An intentional launch date for ustekinumab-ttwe in the United States is set for sometime in February 2025.

The decision target action date was July 7, 2024. At this time, there is no indication from the federal agency to extend the date further.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

A healthy 8-month-old girl awoke with painful indurated red plaques on both cheeks, with the left worse than the right. Her mother said the girl had been sucking on a popsicle for 10 minutes the previous evening before bed. What's the diagnosis?

The primary endpoint of the study was to measure childhood stigma related to disease visibility.

Once-daily, steroid-free, topical roflumilast cream 0.15% has a PDUFA date of July 7, 2024.

What are the skin conditions in which itching becomes the dominant clinical symptom in children?

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the June 2024 issue of Contemporary Pediatrics.

These data from investigators at Trinity College Dublin highlighted the immune response mechanisms visible in children with atopic dermatitis.

Caregivers and parents should feel empowered to protect their children with sun-safe practices that include sunscreen, sun-protective clothing, and sun-safe activities.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the April 2024 issue of Contemporary Pediatrics.

According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.

Data from a recent study revealed that stigma associated with chronic skin diseases made an impact on the quality of life of affected children and adolescents.

A decision from the federal agency is expected in the fourth quarter of 2024.

The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

A young woman with no significant past medical history returns from hiking with several white-spotted ticks and experiences erythematous papules, rashes, headaches, and fatigue. What’s the diagnosis?